🇺🇸 SECGSK plcDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 22:47:26·⟳ 抓取 22:47:58 +32s·⚡ 决策 10-15 22:49:15 +1m17s·11.7 天前
GSK三位高管经股息再投资机制各自买入少量ADS，属例行PDMR持股披露
这是SEC 6-K例行PDMR持股交易通知，三笔均为派息后DRIP机制自动再投资，非主动增持，金额合计仅约6.6万美元，不含任何经营、业绩、指引、合同或控制权增量信息，对GSK估值无影响，无交易edge。
📄 原文GSK plc↗ 原文
----- a1338z.htm ----- 6-K 1 a1338z.htm DIRECTOR/PDMR SHAREHOLDING a1338z UNITED STATES SECURITIES AND EXCHANGE COMMISS…
不做 GSK plc（GSK.US）
6-K仅披露三位高管经股息再投资(DRIP)被动买入合计约6.6万美元ADS，非主动增持、无金额重大性、无经营或指引增量，属例行法定表格，不构成任何方向性交易edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
GSK三位高管通过股息再投资计划各自被动买入价值1.5万–3.4万美元的ADS，属法定例行披露，非主动择时增持，金额相对公司市值可忽略，不构成可交易事件，回避。
🔎 新鲜度:最早出现 2026-10-15 · 扩散 low · price-in 风险 low ↗
主要风险
- 极小的情绪面解读风险：市场偶将内部人买入视为信心信号，但DRIP自动再投资不携带择时信息，不具基本面含义
先例如何影响了这次决策
对本次决策的影响:未因先例改变结论；事件性质本身决定AVOID
方向:无需先例：例行DRIP内部人持股披露不构成方向性事件，历史同类表格普遍无股价反应
涨幅量级:不适用，无ENTER腿故不标定幅度
形态:不适用
原文全文
展开原文 · 4,331 字
----- a1338z.htm -----
6-K
1
a1338z.htm
DIRECTOR/PDMR SHAREHOLDING
a1338z
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the ‘Company’)
Transaction notification
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
American Depositary Shares ('ADS')
ISIN: US37733W2044
b)
Nature
of the transaction
Acquisition of ADS following the re-investment of dividends paid to
shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
$46.9482
326.441
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-13
f)
Place
of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Maya Martinez-Davis
b)
Position/status
President, US
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
American Depositary Shares ('ADS')
ISIN: US37733W2044
b)
Nature
of the transaction
Acquisition of ADS following the re-investment of dividends paid to
shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
$46.9482
351.842
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-13
f)
Place
of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Shobie Ramakrishnan
b)
Position/status
Chief Digital and Technology Officer
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
American Depositary Shares ('ADS')
ISIN: US37733W2044
b)
Nature
of the transaction
Acquisition of ADS following the re-investment of dividends paid to
shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
$46.9482
724.875
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-13
f)
Place
of the transaction
New York Stock Exchange (XNYS)
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at
www.gsk.com
.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: October
15, 2026
By:/s/ VICTORIA
WHYTE
--------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
6-K
1
a1338z.htm
DIRECTOR/PDMR SHAREHOLDING
a1338z
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the ‘Company’)
Transaction notification
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
American Depositary Shares ('ADS')
ISIN: US37733W2044
b)
Nature
of the transaction
Acquisition of ADS following the re-investment of dividends paid to
shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
$46.9482
326.441
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-13
f)
Place
of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Maya Martinez-Davis
b)
Position/status
President, US
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
American Depositary Shares ('ADS')
ISIN: US37733W2044
b)
Nature
of the transaction
Acquisition of ADS following the re-investment of dividends paid to
shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
$46.9482
351.842
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-13
f)
Place
of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Shobie Ramakrishnan
b)
Position/status
Chief Digital and Technology Officer
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
American Depositary Shares ('ADS')
ISIN: US37733W2044
b)
Nature
of the transaction
Acquisition of ADS following the re-investment of dividends paid to
shareholders on 8 October 2026
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
$46.9482
724.875
d)
Aggregated
information
Aggregated
volume
Price
N/A (single transaction)
e)
Date
of the transaction
2026-10-13
f)
Place
of the transaction
New York Stock Exchange (XNYS)
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at
www.gsk.com
.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: October
15, 2026
By:/s/ VICTORIA
WHYTE
--------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
e3f5d335d9· 2026-10-15 22:49 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前